Researchers at the American College of Cardiology’s 2019 Scientific Sessions highlighted promising results from the just-published AUGUSTUS study regarding the use of apixaban for high-risk patients with atrial fibrillation who had acute coronary syndrome or had undergone percutaneous coronary intervention (PCI).
Watch this video for the Lumere team’s insight into what this means for treatment of this patient population and what questions remain unanswered.
We also look at ticagrelor reversal as reported in the PB2452 study.
This Content is provided “AS IS”, with all faults and without any warranty of any kind; any and all warranties are expressly disclaimed. No information in this Content is, or should be construed as medical advice, a guarantee of any product safety or any endorsement of any product or service; use of this Content is at your own risk. Lumere shall not be liable, in any way, for any use of this Article or decisions made and/or actions taken based upon the contents herein. Discussion of experimental uses of drugs or medical product as described in this Content is for informational purposes only, and is not to be interpreted as an endorsement or encouragement of off-label use of any product.